About: Glenn D Flux

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Glenn D Flux Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) эрдэмтэн (mn) वैज्ञानिक (hi) باحت (ary) 研究者 (zh) հետազոտող (hy)
rdfs:label	Glenn D Flux (en) Glenn D Flux (es) Glenn D Flux (nl) Glenn D Flux (sl) Glenn D Flux (ast)
skos:prefLabel	Glenn D Flux (en) Glenn D Flux (es) Glenn D Flux (nl) Glenn D Flux (sl) Glenn D Flux (ast)
name	Glenn D Flux (en) Glenn D Flux (es) Glenn D Flux (nl) Glenn D Flux (sl) Glenn D Flux (ast)
given name	wds:Q50597251-D135546F-ED7F-4E55-95B6-4CFB280CC2CB
given name	Glenn
instance of	wds:Q50597251-74C82CFD-9D0B-4AAE-9960-60888B6BB0B9
instance of	Homo sapiens
skos:altLabel	Glenn Flux (en)
occupation	wds:Q50597251-E43DB1B1-A3D2-4563-8908-03E7BDD29E39
employer	wds:Q50597251-ED377876-7C76-4505-B2C4-28D743176D22
VIAF ID	wds:Q50597251-A4851E9F-22E6-4308-B485-377321CFF722
Library of Congress authority ID	wds:Q50597251-A71E218C-DFBB-4E5A-B2A4-511BC5190A0B
IdRef ID	wds:Q50597251-20f0bc9d-5641-4a74-822d-814cf05b918b
educated at	wds:Q50597251-BF82CAA1-34A6-4283-AB33-F05352ADC87E wds:Q50597251-D53F90DF-FB0B-4546-84A5-805A15E429CC
WorldCat Identities ID (superseded)	wds:Q50597251-03EA756A-1E6C-4892-8CE4-7DFF8F139E50
VIAF ID	http://viaf.org/viaf/225448824
Library of Congress authority ID	http://id.loc.gov/authorities/names/nb2012001057
IdRef ID	http://www.idref.fr/24180504X/id
occupation	researcher
employer	Cancer Research Institute
VIAF ID	225448824
Library of Congress authority ID	nb2012001057
IdRef ID	24180504X
educated at	University of London Cancer Research Institute
WorldCat Identities ID (superseded)	lccn-nb2012001057
ORCID iD	wds:Q50597251-A06AE2BE-4CDE-46E4-9621-6B89C31C1D90
ORCID iD	https://orcid.org/0000-0003-4743-2276
ORCID iD	0000-0003-4743-2276
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q50597251
is author of	EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. Clinical applications of dosimetry for mIBG therapy. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry. Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma Dosimetry for Fractionated 131I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases EANM procedure guideline for treatment of refractory metastatic bone pain A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Development of patient-specific molecular imaging phantoms using a 3D printer. Application of the linear-quadratic model to combined modality radiotherapy The use of BED and EUD concepts in heterogeneous radioactivity distributions on a multicellular scale for targeted radionuclide therapy InfuShield: a shielded enclosure for administering therapeutic radioisotope treatments using standard syringe pumps The importance of the accuracy of image registration of SPECT images for 3D targeted radionuclide therapy dosimetry. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system. Whole-body dosimetry for targeted radionuclide therapy using spectral analysis Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy. Molecular radiotheranostics for neuroendocrine tumours. Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer. Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. Quantitative PET and SPECT performance characteristics of the Albira Trimodal pre-clinical tomograph. The effect of energy and source location on gamma camera intrinsic and extrinsic spatial resolution: an experimental and Monte Carlo study Monte Carlo Evaluation of Auger Electron-Emitting Theranostic Radionuclides. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. From fixed activities to personalized treatments in radionuclide therapy: lost in translation? Dosimetry-based treatment for Graves' disease.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software